Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis

1aforearlymultiplesclerosis:CHAMPStrialsubgroup analyses. Ann Neurol. 2002;51:481-490. 42. Hadjimichael O, Vollmer TL. Adherence to injection therapy in multiple sclerosis: patients survey. Neurology. 1999;52:A549. 43. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 1996;47:889-894. 44. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004; 62:2031-2037. 45. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis: Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998;50:1266-1272. 46. Rice G. The significance of neutralizing antibodies inpatientswithmultiplesclerosis treatedwith interferon beta. Arch Neurol. 2001;58:1297-1298. 47. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis—a geographically based study, 2: predictive value of the early clinical course. Brain. 1989;112:1419-1428. 48. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis—a geographically based study, 3: multivariate analysis of predictive factors and models of outcome. Brain. 1991;114:1045-1056. 49. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol. 1994;241: 597-604. 50. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103:281-300.